There were 3 patients with dedifferentiated chondrosarcoma at our hospital from 1995 to 2013. They were not included because their outcome and management differed to that for conventional chondrosarcoma. The first patient who had no metastasis at presentation survived 5 years eventfree after limb ablation and chemotherapy. The second patient died from pulmonary metastasis 4 months after forequarter amputation. The third patient underwent knee disarticulation for a nonmetastasised uncommon osteolytic lesion at the distal tibia with pathological fracture; he was lost to followup because he lived in a remote area and could not be contacted.
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Correlation between survival and tumour characteristics in patients with chondrosarcoma
To the Editor:
We read with interest the article by Kamal et al. 1 Dedifferentiated chondrosarcoma accounts for approximately 10% of all chondrosarcomas. It has an abrupt transition to foci that have dedifferentiated into a higher grade with a more aggressive component. [2] [3] [4] Its rate of metastasis is high and its 5-year survival is <25%. 4, 5 What was the incidence of the dedifferentiated chondrosarcoma in your series? What was the 5-year event-free survival? Chemotherapy is more effective in mesenchymal chondrosarcoma and dedifferentiated chondrosarcoma than in conventional chondrosarcoma. [2] [3] [4] Was chemotherapy given? What was the response? Did any patient sustain pathological fracture? What was the outcome in these patients?
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